WE CAN POSITIVELY IMPACT THE LIFE OF PATIENTS THROUGH LONG-ACTING INJECTABLES. LATEST NEWS PHASE 3 DATA OF MDC-IRM FIRST PRODUCT BASED ON MEDINCELL’S TECHNOLOGY, SHOWS SIGNIFICANT IMPROVEMENTS IN PATIENTS WITH SCHIZOPHRENIA “Increasing adherence effectiveness may have a far greater impact than any improvement in specific medical treatments.” World Health Organization, Adherence to long-term therapies, Evidence for action (2003) Improving Adherence Many medications aren’t taken as prescribed leading to enormous costs worldwide due to non-adherence. In the US alone, the cost of non-adherence is close to 300 billion USD per year according to the CDC. BEPO® greatly reduces the issues related to adherence while providing more convenience for the patient and clinician. Due to improved adherence, treatment results are better with a lesser likelihood of relapse necessitating treatment extension or re-hospitalization. Addressing tolerance On average there are 70 side effects per prescription drug. Side effects are typically very uncomfortable for patients and this is one of the main reasons for non-adherence. BEPO® requires a significantly lower API load compared to oral treatment. BEPO® reduces side effects making it more comfortable for patients. Affordability In many countries around the globe, more than half and sometimes up to 100% of health care expenditures are out of pocket. Millions of patients worldwide forego treatment for economic reasons. Our low development and production costs combined with a fair business model enable us to reach out to emerging countries. This is the way medicine should be. We’re addressing the greatest global health challenge of the century. Reducing waste Between 30 – 90% of orally administered doses are generally excreted as active substances from the human body. Thanks to localized release of a very low API dosage, BEPO® reduces overall waste including patient API excretion which is considered to be the primary path by which APIs enter the environment. BEPO® By offering a consistent release at a therapeutic level of API, BEPO® could increase the efficacy of treatment compared with traditional methods which alternate between low and high API dispersion/concentration. We’re currently working with academic scientists from around the world to validate the improved efficacy of controlled LAI treatment. Discover BEPO® MC FLUIDICS Our MC Fluidics team is setting up innovative tools to implement an optimized and automated process for lead formulation research. This helps not only to optimize resource management but also to draw parallels between the various tests and to achieve economies of scale. Discover MC Fluidics We’re always looking for new talent Careers The people of MedinCell aren’t just creating life-sustaining products their aim is to revolutionize the patient’s way of life. Interested in being part of an employee owned, creative workplace? Take a look at what our employees had to say. See our job opportunities and apply Subject Partnership Development Scientific collaboration Press and communication Administration People Stay tuned, leave your email I read and accept the privacy policy HOME WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS Copyright © 2021 MedinCell. All rights reserved. | Legal | Privacy | #BetterMedicineForAll | #ImpactHealth | WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS